NeuroOne Regains Compliance with Nasdaq Minimum Bid Price Requirement
NeuroOne Medical Technologies Corporation announced it has regained compliance with Nasdaq's minimum bid price rule following a 1-for-6 reverse stock split, ensuring its continued listing on the Nasdaq Capital Market.
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced today that it has received a notification letter from Nasdaq confirming the company has regained compliance with the Minimum Bid Price Requirement under Nasdaq Marketplace Rule 5550(a)(2), effectively closing the matter. The news comes after the company executed a 1-for-6 reverse stock split that took effect on April 15, 2026, allowing its stock price to meet the $1 per share threshold.
The company initially faced a non-compliance notice on May 6, 2025, when its common stock closed below the $1 minimum bid price for 30 consecutive business days. Nasdaq granted a 180-day extension on November 4, 2025, giving NeuroOne until May 4, 2026, to rectify the issue. The reverse stock split, which began trading on a split-adjusted basis on April 16, 2026, successfully brought the share price into compliance.
This development is significant for NeuroOne as it ensures the company remains listed on the Nasdaq Capital Market, avoiding potential delisting that could have negatively impacted investor confidence and liquidity. Maintaining a Nasdaq listing is crucial for the company's visibility and access to capital markets as it continues to develop and commercialize its medical technology solutions.
NeuroOne is a medical technology company focused on improving surgical care for patients with neurological disorders. The company markets a minimally invasive electrode technology platform with four FDA-cleared product families, including Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These technologies aim to reduce hospitalizations and surgical procedures while improving patient outcomes by offering both diagnostic and therapeutic functions.
Beyond its current product lines, NeuroOne is engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. The company's ability to maintain its Nasdaq listing is key to funding these future innovations and expanding its footprint in the neurological medical device market.
For more information about NeuroOne and its technologies, visit nmtc1.com.